Exact Sciences launches cancer therapy selection test

[Image courtesy of Exact Sciences]Exact Sciences (Nasdaq:EXAS) announced that it launched its OncoExTra cancer therapy selection test in the U.S.

OncoExTra is a next-generation sequencing, comprehensive DNA- and RNA-based genomic test. Madison, Wisconsin-based Exact Sciences designed it to provide doctors and patients a complete molecular picture of the patient’s cancer. The test provides reliable and actionable results personalized to each patient.

Comprehensive genomic profiling (CGP) helps patients understand their cancer and guide treatment. Personalized medicine powered by CGP helps oncologists understand the unique biology of each patient’s tumor. Oncologists can then prescribe treatments determined to offer the best outcomes, according to a news release.

“The OncoExTra test substantially enhances our ability to characterize and understand solid tumors, giving our patients the best chance at treating their cancer successfully,”…

Read more
  • 0

Phillips-Medisize, Exact Sciences to collaborate on colorectal cancer screening

Phillips-Medisize and Exact Sciences (NSDQ:EXAS) today announced a collaboration to advance early cancer detection.

The collaboration centers around Exact Sciences’ Cologuard, the first and only FDA-approved, non-invasive stool DNA screening test for colorectal cancer, according to a news release.

Phillips-Medisize, a Molex company, said the collaboration will seek to focus on the patient experience through the simplicity and convenience of at-home testing. The company developed new tooling to safeguard against inadvertent leaks while meeting specifications and tolerances required to produce the highest levels of product quality.

Exact Sciences was able to utilize supply chain flexibility to acquire all components needed to rapidly scale production of the kit, while Phillips-Medisize located and validated alternate supply sources, conducted risk assessments and forecasting and created sourcing and procurement plans to protect against unplanned disr…

Read more
  • 0